HCCP for Vocal Fold Medialization

We are developing the use of Hyper-crosslinked Carbohydrate Polymer in vocal fold medialization. This biocompatible bulking agent is designed to treat unilateral vocal fold paralysis by restoring glottic closure and improving voice quality. It offers longer retention, minimal immune response, and superior shape and volume maintenance compared to current options.

Targeting a $250 million market with 75,000 cases annually in the U.S., the injectable formulation is in development with FDA pre-submission pending. Preclinical data from sheep studies and histology support its safety and effectiveness.

Projected peak sales are $120 million annually.
There is currently no ideal product on the market, making this a strong opportunity for clinical impact.